Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,062 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Folinic Acid Clear all
Terminated Phase 3 Interventional

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

NCT00077233
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, 5-FU, irinotecan, leucovorin, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
77
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

NCT03798626
View directory record Official record
Conditions
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
Interventions
Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

NCT06948448
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab, Leucovorin
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00042861
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine, fluorouracil, leucovorin calcium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 3, 2026, 10:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors

NCT00001579
View directory record Official record
Conditions
Lymphoma, Neoplasms
Interventions
5-Fluorouracil, Ethynyluracil, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2006 · Synced Sep 3, 2026, 10:27 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

NCT04068103
View directory record Official record
Conditions
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Interventions
Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation
Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
932
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 3, 2026, 10:27 AM EDT
Not listed Phase 1 Interventional

Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00024310
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
folic acid, lometrexol, paclitaxel
Dietary Supplement · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

NCT00336024
View directory record Official record
Conditions
Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Quality-of-Life Assessment, Thiotepa, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
129
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

NCT02631876
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Interventions
Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
53
States / cities
Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

NCT00009893
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
19
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

NCT01231399
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, everolimus, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis
Drug · Other · Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

NCT01814501
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
panitumumab, irinotecan hydrochloride, fluorouracil, leucovorin calcium
Biological · Drug
Lead sponsor
John Hays
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 3, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

NCT04587128
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

NCT00004102
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma

NCT00786643
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-Fluorouracil, Leucovorin (LV), Gamma-Interferon-1b (IFN-γ), Bevacizumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Sep 3, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

NCT00126191
View directory record Official record
Conditions
Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Folic Acid Supplementation in Women of Child Bearing Age

NCT01841658
View directory record Official record
Conditions
Obesity
Interventions
Folic acid
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 3, 2026, 10:27 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

NCT06509906
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Denver, Colorado • Pennington, New Jersey • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

NCT00193219
View directory record Official record
Conditions
Colon Cancer
Interventions
Bevacizumab, Cetuximab, 5-fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
10
States / cities
Evansville, Indiana • Louisville, Kentucky • Portland, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1

NCT00158171
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
Nicotine Replacement Therapies, Nicotine patch, Folic Acid
Drug · Dietary Supplement
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
13 Years to 18 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

NCT03207724
View directory record Official record
Conditions
Pancreatic Cancer, Cachexia, Weight Loss
Interventions
Xilonix plus Onivyde and 5FU
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 3, 2026, 10:27 AM EDT
Completed No phase listed Observational

Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study

NCT01365975
View directory record Official record
Conditions
Pediatric Leukemia, Other Pediatric Cancers
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 60 Years
Enrollment
1,382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 3, 2026, 10:27 AM EDT